These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 33852183)

  • 1. Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development.
    De Pieri A; Korman BD; Jüngel A; Wuertz-Kozak K
    Adv Biol (Weinh); 2021 Apr; 5(4):e2000168. PubMed ID: 33852183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal models in systemic sclerosis: an update.
    Bi X; Mills T; Wu M
    Curr Opin Rheumatol; 2023 Nov; 35(6):364-370. PubMed ID: 37605874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis.
    Stenström M; Nyhlén HC; Törngren M; Liberg D; Sparre B; Tuvesson H; Eriksson H; Leanderson T
    J Dermatol Sci; 2016 Jul; 83(1):52-9. PubMed ID: 27156795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic sclerosis.
    Asano Y
    J Dermatol; 2018 Feb; 45(2):128-138. PubMed ID: 29226387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential.
    Kim S; Park HJ; Lee SI
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.
    Zhao M; Wu J; Wu H; Sawalha AH; Lu Q
    Clin Rev Allergy Immunol; 2022 Apr; 62(2):273-291. PubMed ID: 33449302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovative antifibrotic therapies in systemic sclerosis.
    Beyer C; Distler O; Distler JH
    Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current advances in the treatment of systemic sclerosis.
    Bukiri H; Volkmann ER
    Curr Opin Pharmacol; 2022 Jun; 64():102211. PubMed ID: 35447517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Costimulatory Pathways in Systemic Sclerosis.
    Boleto G; Allanore Y; Avouac J
    Front Immunol; 2018; 9():2998. PubMed ID: 30619351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging targeted therapies in scleroderma lung and skin fibrosis.
    Maurer B; Distler O
    Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phototherapy: a promising treatment option for skin sclerosis in scleroderma?
    Sunderkötter C; Kuhn A; Hunzelmann N; Beissert S
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii52-iii54. PubMed ID: 16987838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular and cellular pathways as treatment targets for biologic therapies in systemic sclerosis.
    Dimitroulas T; Daoussis D; Garyfallos A; Sfikakis PP; Kitas GD
    Curr Med Chem; 2015; 22(16):1943-55. PubMed ID: 25850767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis.
    Kondo M; Suzuki T; Kawano Y; Kojima S; Miyashiro M; Matsumoto A; Kania G; Błyszczuk P; Ross RL; Mulipa P; Del Galdo F; Zhang Y; Distler JHW
    Arthritis Res Ther; 2022 Sep; 24(1):210. PubMed ID: 36050717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis.
    Kim Y; Nam Y; Rim YA; Ju JH
    Stem Cell Res Ther; 2022 Jul; 13(1):303. PubMed ID: 35841004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis.
    Hasegawa M
    J Dermatol; 2010 Jan; 37(1):3-10. PubMed ID: 20175836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
    Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
    Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Old medications and new targeted therapies in systemic sclerosis.
    Nagaraja V; Denton CP; Khanna D
    Rheumatology (Oxford); 2015 Nov; 54(11):1944-53. PubMed ID: 25065013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors.
    Maria ATJ; Partouche L; Goulabchand R; Rivière S; Rozier P; Bourgier C; Le Quellec A; Morel J; Noël D; Guilpain P
    Front Immunol; 2018; 9():3112. PubMed ID: 30687318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.